MU012.C4

General

Cell Line

hPSCreg name MUi026-A
Cite as:
MUi026-A (RRID:CVCL_A6IZ)
Alternative name(s)
MU012.C4
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
FRIMOi003-A
(STGD1_ FiPS4F1.5)
Donor diseases:
Stargardt Disease
LUMCi022-A
(115-1, LUMC0115iATAX01)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi022-B
(115-2, LUMC0115iATAX02)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi022-C
(115-7, LUMC0115iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
RMCGENi020-A
(IPS15-00004)
Donor diseases:
Stargardt Disease
RMCGENi021-A
(IPS22-00087)
Donor diseases:
Stargardt Disease
SCTCi017-A
(IPS15-00006)
Donor diseases:
Stargardt disease
SCTCi018-A
(IPS15-00007)
Donor diseases:
Stargardt disease
ZZUi017-A
(ZZU-iPS-SCA6-001)
Donor diseases:
Spinocerebellar Ataxia Type 6
AIBNi015-A
(SPG1-AU01C15)
Donor diseases:
hereditary spastic paraplegia 56
UKBi014-A
(A-257s2)
Donor diseases:
Walker-Warburg syndrome
FRIMOi004-A
(STGD2_ FiPS4F1.7)
Donor diseases:
Stargardt Disease
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
LUMCi002-A
(113-6, LUMC0113iATAX06)
Donor diseases:
Spinocerebellar Ataxia Type 1
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
LUMCi002-B
(113-7, LUMC0113iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-C
(113-8, LUMC0113iATAX08)
Donor diseases:
Spinocerebellar Ataxia Type 1
ZZUi026-A
(ZZU-iPS-SCA3-003)
Donor diseases:
Spinocerebellar Ataxia Type 3
HDZi003-A
(hiPSC NP0038)
Donor's gene variants:
TMEM43
Donor diseases:
arrhythmogenic right ventricular dysplasia 5
IDIBGIi002-A
(RB20234)
Donor diseases:
Brugada syndrome
IDIBGIi004-A
(RB20236)
Donor diseases:
Brugada syndrome
VUi011-A
(SCZ 3.5)
Donor diseases:
Schizophrenia
ZZUi030-A
(ZZU-iPS-SPG7-001)
Donor diseases:
Spastic paraplegia type 7
UPITTi004-A
(CN090 C5A5J2)
Donor diseases:
Sickle cell anemia
UPITTi004-B
(CN090 C1B5B5)
Donor diseases:
Sickle cell anemia
DHMi004-A
(HOS_1460)
Donor diseases:
Holt-Oram Syndrome
Last update 3rd May 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Mahidol University (MU)
Owner Mahidol University (MU)
Distributors
Derivation country Thailand

External Databases

Cellosaurus CVCL_A6IZ
Wikidata Q107116448
BioSamples SAMEA13819041

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex female
Ethnicity Thai

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is affected.
Synonyms
  • Polycystic kidneys - adult type
  • Autosomal dominant adult polycystic kidney disease
  • ADPKD
  • adult type autosomal dominant polycystic kidney disease
  • Polycystic kidney disease, adult type (disorder)
  • Autosomal dominant polycystic kidney disease
  • polycystic kidney disease, adult type
  • ADPKD - Autosomal dominant polycystic kidney disease
  • polycystic kidney, autosomal dominant
  • polycystic kidney disease, autosomal dominant
  • autosomal dominant polycystic kidney disease
  • congenital biliary ectasias
show more synonyms

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA14307688

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? No
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? No
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? No
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Committee on Human Rights Related to Research Involving Human Subjects, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Approval number MURA2015/674
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Addgene

hIPSC Derivation

General

Source cell type

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Morphology and marker expression
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
NANOG
Yes
SOX2
Yes
DNMT3B
Yes
GABRB3
Yes
GDF3
Yes
TDGF1
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
AFP
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Alpha smooth muscle actin
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
Beta III tubulin
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)